BMEA vs. SVRA, TRDA, HROW, EOLS, ANAB, WVE, RPTX, RNA, PAHC, and TBPH
Should you be buying Biomea Fusion stock or one of its competitors? The main competitors of Biomea Fusion include Savara (SVRA), Entrada Therapeutics (TRDA), Harrow Health (HROW), Evolus (EOLS), AnaptysBio (ANAB), Wave Life Sciences (WVE), Repare Therapeutics (RPTX), Avidity Biosciences (RNA), Phibro Animal Health (PAHC), and Theravance Biopharma (TBPH). These companies are all part of the "pharmaceutical preparations" industry.
Biomea Fusion (NASDAQ:BMEA) and Savara (NASDAQ:SVRA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, institutional ownership, profitability, risk, community ranking, earnings, analyst recommendations and valuation.
Savara has higher revenue and earnings than Biomea Fusion. Savara is trading at a lower price-to-earnings ratio than Biomea Fusion, indicating that it is currently the more affordable of the two stocks.
Savara received 254 more outperform votes than Biomea Fusion when rated by MarketBeat users. Likewise, 65.34% of users gave Savara an outperform vote while only 55.56% of users gave Biomea Fusion an outperform vote.
In the previous week, Biomea Fusion and Biomea Fusion both had 2 articles in the media. Savara's average media sentiment score of 1.00 beat Biomea Fusion's score of 0.89 indicating that Savara is being referred to more favorably in the news media.
93.7% of Biomea Fusion shares are owned by institutional investors. Comparatively, 97.3% of Savara shares are owned by institutional investors. 26.3% of Biomea Fusion shares are owned by insiders. Comparatively, 4.6% of Savara shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Savara's return on equity of -41.62% beat Biomea Fusion's return on equity.
Biomea Fusion presently has a consensus price target of $43.88, suggesting a potential upside of 240.38%. Savara has a consensus price target of $5.00, suggesting a potential upside of 38.12%. Given Biomea Fusion's higher probable upside, equities analysts clearly believe Biomea Fusion is more favorable than Savara.
Biomea Fusion has a beta of -1.05, indicating that its stock price is 205% less volatile than the S&P 500. Comparatively, Savara has a beta of 0.87, indicating that its stock price is 13% less volatile than the S&P 500.
Summary
Savara beats Biomea Fusion on 11 of the 15 factors compared between the two stocks.
Get Biomea Fusion News Delivered to You Automatically
Sign up to receive the latest news and ratings for BMEA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BMEA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Biomea Fusion Competitors List
Related Companies and Tools
